12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Gevokizumab: Phase I/II started

Xoma said NIH's National Eye Institute began an open-label, U.S. Phase I/II trial to evaluate 60 mg gevokizumab every 4 weeks for 16 weeks in 10 patients. Responders, defined as patients who experience a 2-step reduction on a 5-point scale from 0 to 4 or reach...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >